The recent House Appropriations Committee’s FDA report is more than a funding document—it is a policy statement about the future of American biomedical leadership. At a time when scientific innovation is outpacing regulatory structures, this report sends a clear and necessary message: the FDA must evolve from a reactive gatekeeper into a proactive partner in medical progress.
For too long, the conversation around the FDA has been framed as a binary choice between speed and safety. That’s a false choice—and this report rightly rejects it. The real issue is not whether the FDA should regulate, but how it regulates. In the 21st century, effective regulation requires collaboration, scientific engagement, and—critically—predictability.
The FDA Must Be a Partner, Not Just a Referee
If the United States intends to remain the global leader in biopharmaceutical innovation, the FDA cannot simply sit at the end of the development pipeline blowing a whistle. It must be embedded throughout the process as a scientific and regulatory partner.
Breakthroughs in gene editing, cell therapy, and precision medicine are not incremental—they are paradigm-shifting. Applying outdated regulatory frameworks to these technologies is not caution; it is obstruction. The report’s emphasis on modernizing pathways to reduce bureaucratic friction is not just welcome—it is overdue.
A more engaged FDA—one that provides early, continuous, and meaningful feedback—does not weaken oversight. It strengthens it. It allows problems to be identified earlier, solutions to be developed faster, and patients to gain access to therapies sooner. That is what smart regulation looks like.
Equally important, this partnership model is an economic imperative. Capital flows where there is clarity. When regulatory expectations are opaque or inconsistent, investment stalls. When the FDA acts as a transparent, scientifically grounded partner, it de-risks innovation and unlocks the private-sector investment necessary to drive the next generation of cures.
Regulatory Predictability Is Not Optional
Let’s be clear: the single greatest barrier to innovation is not regulation—it is regulatory unpredictability.
Biopharmaceutical companies can navigate high standards. What they cannot navigate is shifting goalposts. The report’s focus on providing regulatory speed anchored in scientific rigor speaks directly to this problem. Developers need to know what evidence is required, how it will be evaluated, and when decisions will be made. That is not a luxury—it is the foundation of a functioning innovation ecosystem.
Predictability does not mean rubber-stamping approvals. It means consistency, transparency, and accountability. It means that similar products are evaluated under similar standards. It means that guidance documents are not suggestions, but reliable frameworks. And it means that timelines are not aspirational—they are commitments.
Without this level of predictability, the United States risks ceding its leadership to more agile regulatory environments abroad. That is not a theoretical concern—it is already happening.
Investing in the FDA Is Investing in Innovation
The report’s $7.1 billion funding framework is not excessive—it is essential. A 21st-century FDA cannot operate with 20th-century resources.
These investments are targeted where they matter most:
- Accelerating Next-Generation Therapies: Modernizing review pathways to keep pace with scientific innovation is critical to avoiding unnecessary delays in areas like gene editing and precision oncology.
- Driving Investment Certainty: Timely, science-based regulatory decisions create the confidence needed to sustain high-risk biomedical research.
- Rebuilding Manufacturing Leadership: Onshoring and advanced manufacturing are not just economic policies—they are national security imperatives.
- Supporting Orphan Drug Development: Rare disease patients cannot afford regulatory inefficiency. Streamlined, predictable pathways are essential.
An under-resourced FDA is not a tougher regulator—it is a slower, less predictable one. That is bad for industry, bad for patients, and bad for public health.
Oversight and Innovation Are Not Opposites
The report also reinforces a critical point often lost in policy debates: strong oversight and strong innovation are mutually reinforcing.
Enhanced foreign inspections level the playing field for U.S. manufacturers and protect the integrity of the supply chain. Initiatives linking nutrition policy to chronic disease prevention reflect a broader, smarter approach to public health. And addressing failures in areas like infant formula is essential to restoring public trust. Trust is not built through rhetoric—it is built through competence, consistency, and transparency. That is what this report aims to deliver.
The Next Step: A Smarter Regulatory State
If anything, this report should be viewed as a starting point. The FDA must continue to modernize by embracing tools such as AI-driven regulatory analytics, real-time safety monitoring, and regulatory sandboxes that allow innovation to be tested without unnecessary delay. The goal is not a weaker FDA. The goal is a smarter FDA—one that understands that in a world of exponential science, linear regulation is a liability.
Conclusion
This report gets the big picture right. Medical innovation and national resilience are not separate priorities—they are the same priority. A predictable, well-resourced FDA that acts as both regulator and partner is not just good policy—it is a strategic necessity. The question is not whether we can afford to make these changes. It is whether we can afford not to.
Peter J. Pitts, a former FDA Associate Commissioner, is President of the Center for Medicine in the Public Interest
